SFX by Ex Libris Inc.

Title:	Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance
Source:	Nature [0028-0836] Kurtova, A V yr:2014

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Powles, T. "MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer." Nature 515.7528 (2014): 558-62.
description	2.	Brownlie, Rebecca J. "T cell receptor signalling networks: branched, diversified and bounded." Nature reviews. Immunology 13.4 (2013): 257-269.
description	3.	Volkmer, J. "Three differentiation states risk-stratify bladder cancer into distinct subtypes." Proceedings of the National Academy of Sciences of the United States of America 109.6 (2012): 2078-2083.
description	4.	Davis, A J J. "Repopulation of tumour cells between cycles of chemotherapy: a neglected factor." The lancet oncology 1.2 (2000): 86-93.
description	5.	Pouteau, E. "Acetate, propionate and butyrate in plasma: determination of the concentration and isotopic enrichment by gas chromatography/mass spectrometry with positive chemical ionization." Journal of mass spectrometry 36.7 (2001): 798-805.
description	6.	Rosenberg, Jonathan E. "Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial." The Lancet 387.10031 (2016): 1909-1920.
description	7.	Herbst, Roy S. "Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients." Nature 515.7528 (2014): 563-7.
description	8.	Powles, T. "Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial." The lancet. 391.10122: 748-757.
description	9.	Shehata, B. "Stereotatic radiosurgery of 468 brain metastases < or =2 cm: implications for SRS dose and whole brain radiation therapy." International journal of radiation oncology, biology, physics 59.1 (2004): 87-93.
description	10.	Grakoui, A. "The immunological synapse: a molecular machine controlling T cell activation." Science 285.5425 (1999): 221-7.
description	11.	Grass, Niveditha D. "The immune mechanisms of abscopal effect in radiation therapy." Current problems in cancer 40.1 (2016): 10-24.
description	12.	Dhull, Varun S. "Extensive Extranodal Involvement of Rare Sites in Non Hodgkin's Lymphoma Detected on (18)F- FDG PET-CT: A Case Report." Nuclear Medicine and Molecular Imaging (2013): 125-9.
description	13.	Hamid, O. "Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma." The New England journal of medicine 369.2 (2013): 134-144.
description	14.	Girdhani, S. "Biological Effects of Proton Radiation: What We Know and Don't Know." Radiation Research 179.3 (2013): 257-272.
description	15.	Guo, W. "Slug and sox9 cooperatively determine the mammary stem cell state." Cell 148.5 (2012): 1015-1028.
description	16.	Dowdy, D. "Tobacco smoking and bladder cancer." JAMA (Chicago, Ill.) 306.20 (2011): 2216-7.
description	17.	Kepp, O. "Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy." Cancer and Metastasis Reviews 30.1 (2011): 61-69.
description	18.	Kim, John J. "Repopulation of cancer cells during therapy: an important cause of treatment failure." Nature Reviews. Cancer 5.7 (2005): 516-525.
description	19.	Jonkman, Marcel F. "Effects of keratin 14 ablation on the clinical and cellular phenotype in a kindred with recessive epidermolysis bullosa simplex." The Journal of Investigative Dermatology 107.5 (1996): 764-769.
description	20.	SBAI, D. "CONTRIBUTION OF ODD-CHAIN FATTY-ACID OXIDATION TO PROPIONATE PRODUCTION IN DISORDERS OF PROPIONATE METABOLISM." The American journal of clinical nutrition 59.6 (1994): 1332-1337.